Introducing Bifidobacteriumbreve M-16V & Bifidobacterium breve B-3
Morinaga Milk Industry Co., Ltd. was established in 1917 and celebrated its 100th anniversary in 2017. Along this 100 year, the Group has produced a wide range of dairy products and well-known probiotics like human residential bifidobacteria (HRB).
Selected by Mother’s Milk
It has been unveiled by recent studies that Human Residential Bifidobacteria (HRB) species are more commonly found in the infant intestine. HRB also have an advantage in utilization of Human Milk Oligosaccharides (HMOs) found in the human milk and tolerant to the natural antibactecterial factor called lysozyme making it easier to colonize the infant gut.
Bifidobacterium breve M-16V
☑ Probiotic for Preterm Infants
Bifidobacterium breve M-16V is one of the flagship products developed by Morinaga which has been researched mainly for infant health & allergies. Its outstanding efficacy allow it to be used in more than 100 Neonatal Intensive Care Unit (NICU) in Japan. The strain won the NutraIngredients Asia Awards 2019, for the category of Infant Nutrition Ingredient of the Year.
Recommended daily dose: 1 Billion CFU Origin: Human infant intestine (Human Residential Bifidobacteria) Documentation: More than 40 scientific studies Safety: US FDA GRAS/ Infant GRAS
Efficacy Proven in Clinical Studies
Bifidobacterium breve B-3
Towards Healthy Weight Management
Bifidobacterium breve B-3 is another human strain probiotic developed by Morinaga specifically targeting healthy weight management. It is found that obese people have less Bifidobacteria in their intestine as compared to lean people, therefore a close relationship is thought to exist between intestinal microbiota and metabolic syndrome.
Recommended daily dose: 10 Billion CFU Origin: Human infant intestine (Human Residential Bifidobacteria) Documentation: 3 human clinical studies Safety: Proven in clinical studies with no adverse serious side